US 12,297,271 B2
PD-1 single domain antibodies and therapeutic compositions thereof
Rajay A. Pandit, La Jolla, CA (US); John C. Timmer, San Diego, CA (US); Angelica N. Sanabria, La Jolla, CA (US); Florian Sulzmaier, San Diego, CA (US); and Brendan P. Eckelman, Encinitas, CA (US)
Assigned to Inhibrx Biosciences, Inc., La Jolla, CA (US)
Filed by Inhibrx Biosciences, Inc., La Jolla, CA (US)
Filed on Feb. 28, 2024, as Appl. No. 18/589,536.
Application 18/589,536 is a division of application No. 17/524,016, filed on Nov. 11, 2021, granted, now 11,945,869.
Application 17/524,016 is a division of application No. 16/600,298, filed on Oct. 11, 2019, granted, now 11,208,485, issued on Dec. 28, 2021.
Claims priority of provisional application 62/791,152, filed on Jan. 11, 2019.
Claims priority of provisional application 62/744,615, filed on Oct. 11, 2018.
Prior Publication US 2024/0317860 A1, Sep. 26, 2024
Int. Cl. C07K 16/28 (2006.01); C07K 16/30 (2006.01)
CPC C07K 16/2818 (2013.01) [C07K 16/2812 (2013.01); C07K 16/2815 (2013.01); C07K 16/2866 (2013.01); C07K 16/30 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)] 18 Claims
 
1. A method of stimulating or inducing an immune response in a subject, the method comprising administering, to a subject in need thereof, a PD-1-binding polypeptide construct comprising at least one heavy chain only variable domain (PD-1 VHH domain) that specifically binds PD-1, wherein the at least one PD-1 VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 301 or 313, a CDR2 comprising the amino acid sequence of SEQ ID NO: 305 or 314, and a CDR3 comprising the amino acid sequences set forth in SEQ ID NO: 309 or 315.